Skip to main content

Advertisement

Log in

ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

At recurrence of breast cancer, the therapeutic target is the metastases. However, it is current practice to base the choice of systemic treatment on the biomarker profile of the primary tumor. In the present study, confirmatory biopsies were obtained from suspected metastatic lesions and compared with the primary tumors with respect to ER, HER2, and TOP2A. In the prospective tissue-collection study, 81 patients had biopsy from a suspected relapse. Additional archived paired material was included, leaving a total of 119 patients with paired primary tumor, synchronous axillary nodes (available in 52 patients) and asyncronous metastases available for analysis. ER, HER2, and TOP2A expression of primary tumors, axillary nodes and metastases were re-analysed and determined centrally by immunohistochemistry, chromogenic in situ hybridization, and fluorescence in situ hybridization. Of the 81 patients with a biopsy from a suspected relapse, 65 (80%) were diagnosed with recurrent breast carcinoma, 3 (4%) were diagnosed with other malignancies, 6 (7%) had benign conditions, and in 7 (9%) patients the biopsy was non-representative. Discordance in ER, HER2, and TOP2A (aberration vs. normal) status between primary tumor and corresponding asynchronous metastasis was 12% (14/118), 9% (10/114), and 23% (17/75), respectively. There were no significant associations with biomarker discordance and prior adjuvant therapy, or location of biopsy. Expression of ER, HER2, and TOP2A displayed discordance with a sufficient frequency to emphasize the role of confirmatory biopsies from metastatic lesions in future management of recurrent breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Amir E, Clemons M (2009) Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol 10:933–935

    Article  PubMed  Google Scholar 

  2. Broom RJ, Tang PA, Simmons C et al (2009) Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 29:1557–1562

    PubMed  Google Scholar 

  3. Locatelli MA, Curigliano G, Fumagalli L, et al (2010) Should liver metastases of breast cancer be biopsied to improve treatment choice? J Clin Oncol (Meeting Abstracts) 28:CRA1008

    Google Scholar 

  4. Lindstrom LS, Karlsson E, Wilking U, Bergh J (2010) Discordance in Hormone Receptor and HER2 status in breast cancer during tumor progression. SABCS Meeting Abstracts S3-5

  5. Amir E, Clemons M, Freedman OC, et al (2010) Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies. J Clin Oncol (Meeting Abstracts) 28:1007

    Google Scholar 

  6. Gutierrez MC, Detre S, Johnston S et al (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23:2469–2476

    Article  PubMed  CAS  Google Scholar 

  7. Johnston SRD, Saccani-Jotti G, Smith IE et al (1995) Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55:3331–3338

    PubMed  CAS  Google Scholar 

  8. Simmons C, Miller N, Geddie W et al (2009) Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20:1499–1504

    Article  PubMed  CAS  Google Scholar 

  9. Guarneri V, Giovannelli S, Ficarra G et al (2008) Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 13:838–844

    Article  PubMed  CAS  Google Scholar 

  10. Liedtke C, Broglio K, Moulder S et al (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20:1953–1958

    Article  PubMed  CAS  Google Scholar 

  11. Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J (1996) Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14:2584–2589

    PubMed  CAS  Google Scholar 

  12. Li BD, Byskosh A, Molteni A, Duda RB (1994) Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 57:71–77

    Article  PubMed  CAS  Google Scholar 

  13. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A (2005) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93:552–556

    Article  PubMed  CAS  Google Scholar 

  14. Edgerton SM, Moore II D, Merkel D, Thor AD (2003) erbB-2 (HER-2) and breast cancer progression (Miscellaneous Article). Appl Immunohistochem Mol Morphol 11:214–221

  15. Lower EE, Glass E, Blau R, Harman S (2009) HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113:301–306

    Article  PubMed  CAS  Google Scholar 

  16. Wilking U, Karlsson E, Skoog L et al (2011) HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 125:553–561

    Article  PubMed  CAS  Google Scholar 

  17. Tanner M, Jarvinen P, Isola J (2001) Amplification of HER-2/neu and topoisomerase II{alpha} in primary and metastatic breast cancer. Cancer Res 61:5345–5348

    PubMed  CAS  Google Scholar 

  18. Gancberg D, Di Leo A, Cardoso F et al (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13:1036–1043

    Article  PubMed  CAS  Google Scholar 

  19. Gong Y, Booser DJ, Sneige N (2005) Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103:1763–1769

    Article  PubMed  CAS  Google Scholar 

  20. Masood S, Bui MM (2000) Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30:259–265

    PubMed  CAS  Google Scholar 

  21. Ejlertsen B, Jensen MB, Nielsen KV et al (2010) HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol 28:984–990

    Article  PubMed  CAS  Google Scholar 

  22. Knoop AS, Knudsen H, Balslev E et al (2005) Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483–7490

    Article  PubMed  CAS  Google Scholar 

  23. Nielsen KV, Ejlertsen B, Moller S, et al (2008) The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol 47:725–734

    Google Scholar 

  24. Press MF, Sauter G, Buyse M, et al (2011) Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 29:859–867

    Google Scholar 

  25. Ellis MJ, Tao Y, Luo J et al (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380–1388

    Article  PubMed  CAS  Google Scholar 

  26. Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 20:1319–1329

    Article  PubMed  CAS  Google Scholar 

  27. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 25:118–145

    Article  PubMed  CAS  Google Scholar 

  28. Hilton JF, Amir E, Hopkins S, et al (2010) Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-010-1264-6

  29. Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF (2004) Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203:918–926

    Article  PubMed  CAS  Google Scholar 

  30. Carlsson J, Nordgren H, Sjostrom J et al (2004) HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 90:2344–2348

    PubMed  CAS  Google Scholar 

  31. D’Andrea MR, Limiti MR, Bari M et al (2007) Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res Treat 101:279–284

    Article  PubMed  Google Scholar 

  32. Cardoso F, Leo AD, Larsimont D et al (2001) Evaluation of HER2, p53, bcl-2, topoisomerase II-+: heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 12:615–620

    Article  PubMed  CAS  Google Scholar 

  33. Ding L, Ellis MJ, Li S et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999–1005

    Article  PubMed  CAS  Google Scholar 

  34. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C (1999) Genetic instability and darwinian selection in tumours. Trends Cell Biol 9:M57–M60

    Article  PubMed  CAS  Google Scholar 

  35. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J (1999) Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142–150

    Article  PubMed  CAS  Google Scholar 

  36. MacFarlane R, Speers C, Masoudi H, Chia S (2008) Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series. Proceedings of ASCO 2008; Abstr 1000

  37. Mittendorf EA, Wu Y, Scaltriti M et al (2009) Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15:7381–7388

    Article  PubMed  CAS  Google Scholar 

  38. Hurley J, Doliny P, Reis I et al (2006) Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24:1831–1838

    Article  PubMed  CAS  Google Scholar 

  39. Burstein HJ, Harris LN, Gelman R et al (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21:46–53

    Article  PubMed  CAS  Google Scholar 

  40. Harris LN, You F, Schnitt SJ et al (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13:1198–1207

    Article  PubMed  CAS  Google Scholar 

  41. Heim S, Teixeira MR, Dietrich CU, Pandis N (1997) Cytogenetic polyclonality in tumors of the breast. Cancer Genet Cytogenet 95:16–19

    Article  PubMed  CAS  Google Scholar 

  42. Brunelli M, Manfrin E, Martignoni G et al (2009) Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 131:678–682

    Article  PubMed  Google Scholar 

  43. Vance GH, Barry TS, Bloom KJ et al (2009) Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 133:611–612

    PubMed  Google Scholar 

  44. Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis GA, Cohen C (2010) Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol

  45. Marusyk A, Polyak K (2010) Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1805:105–117

    PubMed  CAS  Google Scholar 

  46. Teixeira MR, Pandis N, Bardi G, Andersen JA, Mitelman F, Heim S (1995) Clonal heterogeneity in breast cancer: karyotypic comparisons of multiple intra- and extra-tumorous samples from 3 patients. Int J Cancer 63:63–68

    Article  PubMed  CAS  Google Scholar 

  47. Torres L, Ribeiro FR, Pandis N, Andersen JA, Heim S, Teixeira MR (2007) Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res Treat 102:143–155

    Article  PubMed  Google Scholar 

  48. Symmans WF, Liu J, Knowles DM, Inghirami G (1995) Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol 26:210–216

    Article  PubMed  CAS  Google Scholar 

  49. Kuukasjarvi T, Karhu R, Tanner M et al (1997) Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 57:1597–1604

    PubMed  CAS  Google Scholar 

  50. Stoecklein NH, Klein CA (2010) Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer 126:589–598

    Article  PubMed  CAS  Google Scholar 

  51. Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9:302–312

    Article  PubMed  CAS  Google Scholar 

  52. Bussolati G, Leonardo E (2008) Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 61:1184–1192

    Article  PubMed  CAS  Google Scholar 

  53. Boenisch T (2005) Effect of heat-induced antigen retrieval following inconsistent formalin fixation. Appl Immunohistochem Mol Morphol 13:283–286

    Article  PubMed  CAS  Google Scholar 

  54. Gancberg D, di LA, Rouas G et al (2002) Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J Clin Pathol 55:315–317

    Article  PubMed  CAS  Google Scholar 

  55. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 0 AD;80:1943–1949

  56. Graham AD, Faratian D, Rae F, Thomas JJ (2008) Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 52:847–855

    Article  PubMed  CAS  Google Scholar 

  57. Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Moller S, Ejlertsen B, Mouridsen HT (2007) Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 60:397–404

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jeanette Dupont Jensen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jensen, J.D., Knoop, A., Ewertz, M. et al. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer. Breast Cancer Res Treat 132, 511–521 (2012). https://doi.org/10.1007/s10549-011-1610-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-011-1610-3

Keywords

Navigation